Lack of Chinese Ingredient Threatens Butantan and Fiocruz Vaccines

In SP, there is only enough stock to formulate CoronaVac until the end of January

São Paulo

After a massive public celebration of the approval of vaccines, employees at Instituto Butantan and Fundação Oswaldo Cruz are now awakening from their hangover to face reality.

Brazil’s Covid-19 immunization centers Brazil are worried by the delayed delivery of inputs for drugs promoted by the government of China.

SÃO PAULO, SP, BRASIL, 14-01-2021: Butantan Institute, in São Paulo. (Foto: Eduardo Anizelli/ Folhapress, COTIDIANO) - Folhapress

In Sao Paulo, the remaining stock of the active ingredient of Chinese CoronaVac will only allow production and packaging until the end of January.

At Butantan, 6 million doses were distributed on Sunday (17), between ready-made syringes from China and ampoules filled with the formulated vaccine.

Besides that, the remaining 4.8 million doses will last until January 31st. After that, there is no more supply. The last consignment of inputs that arrived in the country was at the end of the year.

In Rio de Janeiro, the situation is even worse in relation to the vaccine of the British AstraZeneca/University of Oxford: the delivery of the product has not even started, although it has been expected since the end of last year.

Translated by Kiratiana Freelon

Read the article in the original language